We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > stannsoporfin

News List

After AdComm rejection, Mallinckrodt’s stannsoporfin gets stiff-armed at FDA fiercebiotech
August 23, 2018
The FDA has issued a complete response letter to Mallinckrodt’s jaundice drug stannsoporfin. Mallinckrodt plans to talk to the FDA in the coming months before deciding the fate of a drug it acquired in an $80 million buyout last year.
Mallinckrodt to buy InfaCare and its paediatric jaundice treatment stannsoporfin pharmaceutical-technology
August 08, 2017
UK-based pharmaceutical company Mallinckrodt has entered an agreement to acquire InfaCare Pharmaceutical and its developmental product, stannsoporfin, used for the treatment of newborns with the risk of developing severe jaundice.